Fig. 7From: A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2Therapeutic efficacy of 11D9 in beagles. A Weight changes in different groups; B Survival rate of different groups; C and D The HA and qPCR test of the fecal samples from different groups to new CPV-2a; E Pathological results of HE and IHC in the challenge and therapeutic groupsBack to article page